References

1. Leeb-Lundberg LM, Marceau F, Müller-Esterl W, Pettibone DJ, Zuraw BL (2005) International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57: 27-77 [CrossRef] [Google Scholar] [PubMed]
2. Abdella N, Al Arouj M, Al Nakhi A, Al Assoussi A, Moussa M (1998) Noninsulin- dependent diabetes in Kuwait: prevalence rates and associated risk factors. Diabetes Res Clin Pract 42: 187-196 [CrossRef] [Google Scholar] [PubMed]
3. Al-Shoumer KA, Al-Asousi AA, Doi SA, Vasanthy BA (2008) Serum leptin and its relationship with metabolic variables in Arabs with type 2 diabetes mellitus. Ann Saudi Med 28: 367-370 [CrossRef] [Google Scholar] [PubMed]
4. Sharma JN (2006) Role of tissue kallikrein-kininogen-kinin pathways in the cardiovascular system. Arch Med Res 37: 299-306 [CrossRef] [Google Scholar] [PubMed]
5. Rabito SF, Scicli AG, Kher V, Carretero OA (1982) Immunoreactive glandular kallikrein in rat plasma: a radioimmunoassay for its determination. Am J Physiol 242: H602-610 [CrossRef] [Google Scholar] [PubMed]
6. Yayama K, Kunimatsu N, Teranishi Y, Takano M, Okamoto H (2003) Tissue kallikrein is synthesized and secreted by human vascular endothelial cells. Biochim Biophys Acta 1593: 231-238 [CrossRef] [Google Scholar] [PubMed]
7. Katori M, Majima M (2006) A missing link between a high salt intake and blood pressure increase. J Pharmacol Sci 100: 370-390 [CrossRef] [Google Scholar] [PubMed]
8. Sharma JN, Uma K, Yusof AP (1998) Left ventricular hypertrophy and its relation to the cardiac kinin-forming system in hypertensive and diabetic rats. Int J Cardiol 63: 229-235 [CrossRef] [Google Scholar] [PubMed]
9. Sharma JN, Uma K, Noor AR, Rahman AR (1996) Blood pressure regulation by the kallikrein-kinin system. Gen Pharmacol 27: 55-63 [CrossRef] [Google Scholar] [PubMed]
10. Jaffa AA, Durazo-Arvizu R, Zheng D, Lackland DT, Srikanth S, et al. (2003) Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes. Diabetes 52: 1215-1221 [CrossRef] [Google Scholar] [PubMed]
11. Harvey JN, Jaffa AA, Margolius HS, Mayfield RK (1990) Renal kallikrein and hemodynamic abnormalities of diabetic kidney. Diabetes 39: 299-304 [CrossRef] [Google Scholar] [PubMed]
12. Jaffa AA, Rust PF, Mayfield RK (1995) Kinin, a mediator of diabetesinduced glomerular hyperfiltration. Diabetes 44: 156-160 [CrossRef] [Google Scholar] [PubMed]
13. Parappil A, Doi SA, Al-Shoumer KA (2002) Diagnostic criteria for diabetes revisited: making use of combined criteria. BMC Endocr Disord 2: 1 [CrossRef] [Google Scholar] [PubMed]
14. Domke I, Cremer P, Huchtemann M (2000) Therapeutic drug monitoring on COBAS INTEGRA 400--evaluation results. Clin Lab 46: 509-515 [Google Scholar] [PubMed]
15. Jaffa AA, Rust PF, Mayfield RK (1995) Kinin, a mediator of diabetesinduced glomerular hyperfiltration. Diabetes 44: 156-160 [CrossRef] [Google Scholar] [PubMed]
16. Jaffa AA, Miller DH, Bailey GS, Chao J, Margolius HS, et al. (1987) Abnormal regulation of renal kallikrein in experimental diabetes. Effects of insulin on prokallikrein synthesis and activation. J Clin Invest 80: 1651- 1659 [CrossRef] [Google Scholar] [PubMed]
17. Jaffa AA, Vio C, Velarde V, LeRoith D, Mayfield RK (1997) Induction of renal kallikrein and renin gene expression by insulin and IGF-I in the diabetic rat. Diabetes 46: 2049-2056 [CrossRef] [Google Scholar] [PubMed]
18. Sharma JN, Kesavarao U (2007) Changes in plasma prekallikrein activity, blood pressure, and left ventricular thickness in hypertensive and normotensive diabetic rats. Methods Find Exp Clin Pharmacol 29: 75-78 [CrossRef] [Google Scholar] [PubMed]
19. Weinberg MS, Trebbin WM, Solomon RJ (1986) Urinary kininogen: a possible regulator of kinin formation in normal individuals and subjects with essential hypertension, end-satge renal and liver disease. AdvExp Med Biol 198: 119-125 [CrossRef] [Google Scholar] [PubMed]
20. Weinberg MS, Azar P, Trebbin WM, Solomon RJ (1985) The role of urinary kininogen in the regulation of kinin generation. Kidney Int 28: 975-981 [CrossRef] [Google Scholar] [PubMed]
21. Zuccollo A, Navarro M, Catanzaro O (1996) Effects of B1 and B2 kinin receptor antagonists in diabetic mice. Can J Physiol Pharmacol 74: 586- 589 [CrossRef] [Google Scholar] [PubMed]
22. Meng K, Haberland GL (1973) In: Haberland, Rohen JW, eds. Kininogenases Kallikrein. F. K. SchattauerVerlag, Stuttgart, USA,75-80
23. Campbell DJ, Kladis A, Zhang Y, Jenkins AJ, Prior DL, et al. (2010) Increased tissue kallikrein levels in type 2 diabetes. Diabetologia 53: 779- 785 [CrossRef] [Google Scholar] [PubMed]
24. Chao J, Yin H, Gao L, Hagiwara M, Shen B, et al. (2008) Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation. Hypertension 52: 715-720 [CrossRef] [Google Scholar] [PubMed]
25. Christopher J, Jaffa AA (2002) Diabetes modulates the expression of glomerular kinin receptors. Int Immunopharmacol 2: 1771-1779 [CrossRef] [Google Scholar] [PubMed]
26. Sharma JN, Al-Shoumer KA, Matar KM, Al-Gharee HY, Madathil NV (2013) Bradykinin-forming components in Kuwaiti patients with type 2 diabetes. Int J Immunopathol Pharmacol 26: 699-705 [CrossRef] [Google Scholar] [PubMed]
27. Sharma JN, Al-Shoumer K, Matar KM, Madathil NV, Al-Moalem A (2015) Altered activities of kininase II, an angiotensin converting enzyme, prekallikrein, and nitric oxide in Kuwaiti patients with type 2 diabetes. Int J Immunopathol Pharmacol 28: 240-246 [CrossRef] [Google Scholar] [PubMed]